OPKO HEALTH, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
OPK$1.71-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
For the years ended December 31, 2025, 2024, 2023
| Additional · Accumulated Other | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Treasury · Paid-In · Comprehensive · Accumulated | ||||||||
| Shares | Dollars | Shares | Dollars | Capital | Loss | Deficit | Total | |
| Balance at December 31, 2022 | 781,306,164 | $7,813 | (8,655,082) | (1,791) | $3,421,872 | $(43,323) | $(1,822,923) | $1,561,648 |
| Equity-based compensation expense | — | — | — | — | 11,413 | — | — | 11,413 |
| Exercise of common stock options/vesting of restricted stock units | 630,721 | 7 | — | — | (279) | — | — | (272) |
| Net loss | — | — | — | — | — | — | (188,863) | (188,863) |
| Other comprehensive income | — | — | — | — | — | 5,293 | — | 5,293 |
| Balance at December 31, 2023 | 781,936,885 | $7,820 | (8,655,082) | (1,791) | $3,433,006 | $(38,030) | $(2,011,786) | $1,389,219 |
| Additional · Accumulated Other | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Treasury · Paid-In · Comprehensive · Accumulated | ||||||||
| Shares | Dollars | Shares | Dollars | Capital | Loss | Deficit | Total | |
| Balance at December 31, 2023 | 781,936,885 | $7,820 | (8,655,082) | $(1,791) | $3,433,006 | $(38,030) | $(2,011,786) | $1,389,219 |
| Equity-based compensation expense | — | — | — | — | 11,048 | — | — | 11,048 |
| Exercise of common stock options/vesting of restricted stock units | 384,378 | 4 | — | — | (212) | — | — | (208) |
| 2025 Notes | — | — | (21,144,825) | — | — | — | — | — |
| 2029 Convertible Notes | — | — | — | — | 152,041 | — | — | 152,041 |
| Repurchase of 2029 Convertible Notes | — | — | — | — | (25,105) | — | — | (25,105) |
| Shares repurchase | (80,970,816) | (809) | — | — | (89,414) | — | — | (90,223) |
| Net loss | — | — | — | — | — | — | (53,224) | (53,224) |
| Other comprehensive loss | — | — | — | — | — | (18,100) | — | (18,100) |
| Balance at December 31, 2024 | 701,350,447 | $7,015 | (29,799,907) | $(1,791) | $3,481,364 | $(56,130) | $(2,065,010) | $1,365,448 |
| Additional · Accumulated Other | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Stock · Treasury · Paid-In · Comprehensive · Accumulated | ||||||||
| Shares | Dollars | Shares | Dollars | Capital | Loss | Deficit | Total | |
| Balance at December 31, 2024 | 701,350,447 | $7,015 | (29,799,907) | (1,791) | $3,481,364 | $(56,130) | $(2,065,010) | $1,365,448 |
| Equity-based compensation expense | — | — | — | — | 10,714 | — | — | 10,714 |
| Exercise of common stock options/vesting of restricted stock units | 636,832 | 6 | — | — | (262) | — | — | (256) |
| Repurchase of 2029 Convertible Notes | 121,437,998 | 1,214 | — | — | 128,446 | — | — | 129,660 |
| Shares repurchase | (33,507,844) | (335) | (1,050,000) | (1,385) | (45,320) | — | — | (47,040) |
| Net loss | — | — | — | — | — | — | (225,680) | (225,680) |
| Other comprehensive income | — | — | — | — | — | 35,113 | — | 35,113 |
| Balance at December 31, 2025 | 789,917,433 | $7,900 | (30,849,907) | (3,176) | $3,574,942 | $(21,017) | $(2,290,690) | $1,267,959 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.